DRUGS USED IN THE TREATMENT OF CANCER.CONNORS TA.1975; F.E.B.S. LETTERS; NETHERL.; DA. 1975; VOL. 57; NO 3; PP. 223-233; BIBL. 29 REF.Article

POSSIBLE PRO-DRUGS IN CANCER CHEMOTHERAPYCONNORS TA.1980; CHEM. IND. (LOND.); ISSN 0009-3068; GBR; DA. 1980; NO 11; PP. 447-451; BIBL. 18 REF.Article

ANTITUMOUR DRUGS WITH LATENT ACTIVITYCONNORS TA.1978; BIOCHIMIE; FRA; DA. 1978; VOL. 60; NO 9; PP. 979-987; BIBL. 29 REF.Conference Paper

ALKYLATING AGENTSCONNORS TA.1974; TOPICS CURR. CHEM.; GERM.; DA. 1974; VOL. 52; PP. 141-171; BIBL. 2 P. 1/2Article

BIOACTIVATION AND CYTOTOXICITY.CONNORS TA.1976; PROGR. DRUG METABOL.; G.B.; DA. 1976; VOL. 1; PP. 41-75; BIBL. 2 P. 1/2Article

ALKYLATING DRUGS, NITROSOUREAS AND ALKYLTRIAZENESCONNORS TA.1982; CANCER CHEMOTHERAPY; ISSN 505242; NLD; DA. 1982; NO 4; PP. 29-50; BIBL. 159 REF.Article

IN VITRO STUDIES WITH HEXAMETHYLMELAMINE.RUTTY CJ; CONNORS TA.1977; BIOCHEM. PHARMACOL.; G.B.; DA. 1977; VOL. 26; NO 24; PP. 2385-2391; BIBL. 25 REF.Article

THE BINDING OF ¹⁴C LABELLED (1-(2-CHLOROETHYL)-3-CYCLOHEXYL-1-NITROSOUREA (CCNU) TO MACROMOLECULES OF SENSITIVE AND RESISTANT TUMOURS = FIXATION DE LA (CHLORO-2 ETHYL)-1 CYCLOHEXYL-3 NITROSO-1 UREE (CCNU) AUX MACROMOLECULES DES TUMEURS SENSIBLES ET RESISTANTESCONNORS TA; HARE JR.1974; BRIT. J. CANCER; G.B.; DA. 1974; VOL. 30; NO 5; PP. 477-480; BIBL. 20REF.Article

SCREENING FOR ANTI-CANCER AGENTS: THE RELATIVE MERITS OF IN VITRO AND IN VIVO TECHNIQUES.CONNORS TA; PHILLIPS BJ.1975; BIOCHEM. PHARMACOL.; G.B.; DA. 1975; VOL. 24; NO 24; PP. 2217-2223; BIBL. 33 REF.Article

STUDIES OF THE MECAHNISM OF ACTION OF THE TUMOUR-INHIBITORY NITROSOUREAS.CONNORS TA; HARE JR.1975; BIOCHEM. PHARMACOL.; G.B.; DA. 1975; VOL. 24; NO 23; PP. 2133-2140; BIBL. 28 REF.Article

NEW MODELS FOR CANCER CHEMOTHERAPYDETRE SI; DAVIES AJS; CONNORS TA et al.1975; CANCER CHEMOTHERAPY REP., 2; U.S.A.; DA. 1975; VOL. 5; NO 1; PP. 133-143; BIBL. 18 REF.; (SCREENERS CONF. PROC.; SILVER SPRING, MD.; 1975)Conference Paper

IN VITRO METABOLIC ACTIVATION OF 1-P-CARBOXAMIDOPHENYL-3,-3-DIMETHYLTRIAZENE TO CYTOTOXIC PRODUCTS.ABEL G; CONNORS TA; GIRALDI T et al.1977; CANCER LETTERS; NETHERL.; DA. 1977; VOL. 3; NO 5-6; PP. 259-264; BIBL. 11 REF.Article

HEXAMETHYLMELAMINE-INDUCED REGRESSION OF HUMAN LUNG TUMORS GROWING IN IMMUNE DEPRIVED MICE = REGRESSION INDUITE PAR L'HEXAMETHYLMELAMINE DE TUMEURS PULMONAIRES HUMAINES CROISSANT CHEZ DES SOURIS IMMUNOPRIVESMITCHLEY BCV; CLARKE SA; CONNORS TA et al.1975; CANCER RES.; U.S.A.; DA. 1975; VOL. 35; NO 4; PP. 1099-1102; BIBL. 16REF.Article

PHARMACOLOGICALLY ACTIVE POLYMERS, 13. ELUCIDATION OF THE TUMOUR AFFINITY OF POLY (SULFADIAZINEARCRYLAMIDE).ABEL G; CONNORS TA; HOFMANN V et al.1976; MAKROMOLEK. CHEM.; SCHWEIZ; DA. 1976; VOL. 177; NO 9; PP. 2669-2674; ABS. ALLEM.; BIBL. 6 REF.Article

METHYLATION OF CYSTEINE IN HEMOGLOBIN FOLLOWING EXPOSURE TO METHYLATING AGENTSBAILEY E; CONNORS TA; FARMER PB et al.1981; CANCER RES.; ISSN 0008-5472; USA; DA. 1981; VOL. 41; NO 6; PP. 2514-2517; BIBL. 16 REF.Article

APPROACH TO THE QUANTITATION OF ALKYLATED AMINO ACIDS IN HAEMOGLOBIN BY GAS CHROMATOGRAPHY MASS SPECTROMETRYFARMER PB; BAILEY E; LAMB JH et al.1980; BIOMED. MASS SPECTROM.; GBR; DA. 1980; VOL. 7; NO 1; PP. 41-46; BIBL. 19 REF.Article

CHEMOTHERAPY OF HUMAN TUMORS IN T-LYMPHOCYTE-DEFICIENT MICE.MITCHLEY BCV; CLARKE SA; CONNORS TA et al.1977; CANCER TREATM. REP.; U.S.A.; DA. 1977; VOL. 61; NO 3; PP. 451-462; BIBL. 17 REF.Article

REGRESSION OF HUMAN LUNG TUMOR XENOGRAFTS INDUCED BY WATER-SOLUBLE ANALOGS OF HEXAMETHYLMELAMINE.CONNORS TA; CUMBER AJ; ROSS WCJ et al.1977; CANCER TREATM. REP.; U.S.A.; DA. 1977; VOL. 61; NO 5; PP. 927-928; BIBL. 7 REF.Article

AN ATHYMIC NUDE MUTATION IN THE RAT.FESTING MFW; MAY D; CONNORS TA et al.1978; NATURE; GBR; DA. 1978; VOL. 274; NO 5669; PP. 365-366; BIBL. 5 REF.Article

PREPARATION AND ANTITUMOR ACTIVITY OF 1-ARYL-3,3-DIMETHYLTRIAZENE DERIVATIVES.GIRALDI T; NISI C; CONNORS TA et al.1977; J. MEDICIN. CHEM.; U.S.A.; DA. 1977; VOL. 20; NO 6; PP. 850-853; BIBL. 12 REF.Article

TUMOUR INHIBITORY TRIAZENES: STRUCTURAL REQUIREMENTS FOR AN ACTIVE METABOLITECONNORS TA; GODDARD PM; MERAI K et al.1976; BIOCHEM. PHARMACOL.; G.B.; DA. 1976; VOL. 25; NO 3; PP. 241-246; BIBL. 20 REF.Article

THE RELATIONSHIP BETWEEN THE PHARMACOKINETICS OF INTRAVENOUS CISMETHRIN AND BIORESMETHRIN AND THEIR MAMMALIAN TOXICITYGRAY AJ; CONNORS TA; HOELLINGER H et al.1980; PESTIC. BIOCHEM. PHYSIOL.; ISSN 0048-3575; USA; DA. 1980; VOL. 13; NO 3; PP. 281-293; BIBL. 14 REF.Article

THE CLINICAL PHARMACOLOGY OF A HEPATOMA-SPECIFIC ALKYLATING AGENT.CURT GA; CONNORS TA; MURRAY LYON IM et al.1977; BIOCHEM. PHARMACOL.; G.B.; DA. 1977; VOL. 26; NO 18; PP. 1715-1718; BIBL. 5 REF.Article

THE METABOLISM OF THE ANTI-TUMOUR AGENT 1(1-AZIRIDINYL)-2,4-DINITROBENZENE (CB 1837). = LE METABOLISME DE L'AGENT ANTITUMORAL (AZIRIDINYL-1)-1 DINITRO-2,4 BENZENE (CB 1837)CONNORS TA; HICKMAN JA; JARMAN M et al.1975; BIOCHEM. PHARMACOL.; G.B.; DA. 1975; VOL. 24; NO 18; PP. 1665-1670; BIBL. 13 REF.Article

TREATMENT OF A MOUSE LYMPHOMA BY L-ASPARAGINASE: SUCCESS DEPENDS ON THE HOST'S IMMUNE RESPONSECARTER RL; CONNORS TA; WESTON BJ et al.1973; INTERNATION. J. CANCER; SWITZ.; DA. 1973; VOL. 11; NO 2; PP. 345-357; ABS. FR.; BIBL. 18REF.Serial Issue